1. Immunization of Preterm Infants With 10-Valent Pneumococcal Conjugate Vaccine
- Author
-
Andreas Constantopoulos, Antigoni Tsirka, Nancy François, Vassiliki Papaevangelou, Dorota Borys, Marina Anagnostakou, Jose Manuel Merino, Dimitrios Kafetzis, Juan-Carlos Tejedor, Fani Athanassiadou, Lode Schuerman, and Felix Omeñaca
- Subjects
Male ,Immunization, Secondary ,Booster dose ,medicine.disease_cause ,Pneumococcal Infections ,Haemophilus influenzae ,Pneumococcal Vaccines ,Conjugate vaccine ,Humans ,Medicine ,Vaccines, Conjugate ,biology ,business.industry ,Immunogenicity ,Vaccination ,Infant, Newborn ,Infant ,Titer ,Immunization ,Pediatrics, Perinatology and Child Health ,Immunology ,biology.protein ,Female ,Antibody ,business ,Infant, Premature - Abstract
OBJECTIVE: The safety and immunogenicity of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in preterm infants were assessed in this study. METHODS: Three parallel groups of infants received 3-dose primary immunization with PHiD-CV at 2, 4, and 6 months of age and a booster dose at 16 to 18 months: preterm I (gestation period ≥ 27 and RESULTS: The incidence of solicited general symptoms was similar across groups, and the frequency of grade 3 general symptoms was low. Incidences of redness and swelling were generally lower in preterm infants. PHiD-CV was immunogenic for each of the 10 vaccine pneumococcal serotypes (postprimary, ≥92.7% of infants reached enzyme-linked immunosorbent assay antibody concentrations ≥ 0.2 μg/mL and postbooster, ≥97.6%) and for protein D, with a trend for lower postprimary geometric mean antibody concentrations and opsonophagocytic activity (OPA) titers in preterm infants for some pneumococcal serotypes. Postbooster, ≥91.9% of subjects in each group had an OPA titer ≥ 8 for each of the vaccine serotypes. Pneumococcal antibody concentrations and OPA titers after priming and booster vaccination were comparable between the 2 preterm groups. CONCLUSIONS: PHiD-CV was well tolerated and immunogenic in preterm infants when given as a 3-dose primary vaccination, with robust enzyme-linked immunosorbent assay antibody and OPA booster responses in the second year of life.
- Published
- 2011